Literature DB >> 12536121

Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy.

Susan Lowey1.   

Abstract

The primary cause of familial hypertrophic cardiomyopathy (FHC) has been attributed to mutations in the genes that encode the contractile proteins of the muscle cell. A majority of these mutations have been found in myosin, the principal component of the thick filament. Most in vitro studies have concluded that FHC mutations cause a loss of function in the biochemical and mechanical properties of myosin. Hypertrophy would then follow as a compensatory mechanism to raise the work and power output of the failing heart. Several recent studies, however, have thrown this mechanism into doubt by providing evidence that FHC mutations in the myosin heavy chain (MHC) can enhance the functional properties of myosin. This review discusses the problems encountered in reaching a definitive answer on the effect of MHC mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12536121     DOI: 10.1016/s1050-1738(02)00181-0

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  24 in total

Review 1.  Mechanical and energetic consequences of HCM-causing mutations.

Authors:  Cecilia Ferrantini; Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Corrado Poggesi
Journal:  J Cardiovasc Transl Res       Date:  2009-10-09       Impact factor: 4.132

Review 2.  Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.

Authors:  Jil C Tardiff
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

Review 3.  Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.

Authors:  Jeffrey R Moore; Leslie Leinwand; David M Warshaw
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

4.  Localization of the binding site of the C-terminal domain of cardiac myosin-binding protein-C on the myosin rod.

Authors:  Emily Flashman; Hugh Watkins; Charles Redwood
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

5.  Shifts in the myosin heavy chain isozymes in the mouse heart result in increased energy efficiency.

Authors:  Kirsten Hoyer; Maike Krenz; Jeffrey Robbins; Joanne S Ingwall
Journal:  J Mol Cell Cardiol       Date:  2006-10-19       Impact factor: 5.000

6.  Transgenic mouse α- and β-cardiac myosins containing the R403Q mutation show isoform-dependent transient kinetic differences.

Authors:  Susan Lowey; Vera Bretton; James Gulick; Jeffrey Robbins; Kathleen M Trybus
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

7.  The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils.

Authors:  Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Giulia D'Amati; Francesca Girolami; Magdi Yacoub; Franco Cecchi; Iacopo Olivotto; Corrado Poggesi
Journal:  J Physiol       Date:  2008-06-19       Impact factor: 5.182

8.  Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.

Authors:  Mark Luedde; Ulrich Flögel; Maike Knorr; Christina Grundt; Hans-Joerg Hippe; Benedikt Brors; Derk Frank; Uta Haselmann; Claude Antony; Mirko Voelkers; Juergen Schrader; Patrick Most; Bjoern Lemmer; Hugo A Katus; Norbert Frey
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

9.  The myosin C-loop is an allosteric actin contact sensor in actomyosin.

Authors:  Katalin Ajtai; Miriam F Halstead; Miklós Nyitrai; Alan R Penheiter; Ye Zheng; Thomas P Burghardt
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

10.  Myosin dynamics on the millisecond time scale.

Authors:  Thomas P Burghardt; Jimmy Yan Hu; Katalin Ajtai
Journal:  Biophys Chem       Date:  2007-09-11       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.